China Health Group Limited provided earnings guidance for the year ended 31 March 2023. For the period, its expected the Group will record a net loss of approximately HKD 42 million for the year ended 31 March 2023 as compared to a net loss of approximately HKD 12.2 million for the year ended 31 March 2022. The expected increase in loss was mainly attributable to loss on fair value change of contingent consideration of approximately HKD 18 million (2022: gain of approximately HKD 4.8 million) arising from issue of consideration shares in respect of the acquisition of a subsidiary of the Company recognised for the year ended 31 March 2023.

Such fair value change is a non-cash item and does not have an immediate impact on the Group's cash flows and operations.